CCCR Laboratories

The Balis Lab for Cancer Pharmacology optimizes the safety and efficacy of anticancer drugs, develops new childhood cancer drugs, and creates clinical trial designs and endpoints to expedite new treatments.

The Barakat Lab aims to improve health equity for youth with cancer and their families by designing, evaluating, and implementing accessible assessments and interventions targeting medical and psychosocial outcomes across the cancer treatment trajectory.

The Bauer Lab focuses on understanding the molecular landscape of pediatric thyroid cancer to optimize diagnostic accuracy of fine needle aspiration, identify markers predicting invasive behavior and prognosis, and find targets for better treatment options.

The Behavioral Oncology Program aims to improve medical and psychosocial outcomes and health-related quality of life in young patients and their families across the continuum of cancer care.

The Bernt Lab's research program focuses on understanding the molecular makeup of leukemia to develop targeted therapies, with a primary emphasis on epigenetics and transcription.

The Blobel Lab investigates fundamental mechanisms involving transcription factors, chromatin regulators, and higher-order chromatin, aiming its discoveries toward genetic and epigenetic treatment modalities.

The Brodeur Lab focuses on nanoparticle drug delivery and cancer predisposition. They aim to deliver more drugs to tumors, identify new cancer genes, and develop better surveillance techniques to improve outcomes and reduce side effects.

The Bunin Lab study bone marrow and blood transplants for children with cancer. Their goal is to improve outcomes and reduce risks for pediatric oncology transplant patients.

The Cancer Pharmacology Lab supports clinical trials of new targeted and immune-based anticancer drugs by conducting pre-clinical and clinical pharmacology studies.

The Chorny Lab designs drug delivery systems for vascular diseases and high-risk cancers. They optimize biodegradable nanoparticles and prodrugs to enhance therapeutic activity and minimize side effects.

The Chou Lab focuses on regenerative blood cellular therapy, the mechanisms of normal human hematopoietic development, and how these become disrupted in hematologic diseases.

The Cole Lab focuses on finding therapeutic vulnerabilities in specific types of pediatric brain cancers. Their goal is to identify effective therapies and improve cure rates for children with malignant brain tumors.

The Felix Laboratory studies the molecular mechanisms behind chromosomal translocations of the mixed-lineage leukemia gene and their effects on high-risk leukemia in infants and as a chemotherapy complication.

The Grinspan Lab studies oligodendrocytes, which create the myelin sheath needed for nerve transmission. They explore signaling pathways that regulate oligodendrocyte maturation and their disruption in diseases like MS, HIV, and perinatal white matter injury.

The Grupp Lab develops new targeted cancer treatments and cell-based immunotherapies for leukemia and solid tumors. They aim to create advanced, less toxic treatments for children with high-risk cancers.

The Hocking Lab studies the neurodevelopmental effects of surviving childhood cancer or having neurofibromatosis type 1. They aim to identify high-risk individuals and intervene to improve quality of life.

The Hogarty Lab studies neuroblastoma, a childhood tumor causing 15% of childhood cancer deaths. Survivors often face lifelong toxicities from treatments. The lab aims to understand tumor biology and find unique vulnerabilities for better outcomes.

The Hunger Lab uses molecular and genomic approaches to identify and evaluate targeted treatments for children with relapsed or high-risk acute lymphoblastic leukemia (ALL) to develop better therapies, improve cure rates, and minimize treatment toxicities for children with ALL.

The Joffe Lab addresses the ethical challenges that arise during the design and conduct of biomedical research, including clinical trials and genomic research in both adult and pediatric settings.

The Kalish Lab studies the genetic and epigenetic causes of growth disorders and cancer predisposition. They focus on Beckwith-Wiedemann syndrome (BWS), the most common epigenetic and cancer predisposition disorder, and run the BWS registry and biorepository.

The Li Lab for Cancer Diagnostic Innovation Research uses multi-omics analysis and next-gen sequencing to diagnose pediatric tumors, monitor disease progression, and optimize treatment strategies for children with cancer.

The Maris Lab studies molecular and genetic mechanisms of neuroblastoma, a common childhood cancer. They aim to develop new diagnostic tests and targeted therapies, focusing on less toxic treatments and immunotherapy.

The Maude Lab focuses on developing and evaluating new immunotherapies and targeted therapies for children with high-risk and relapsed/refractory acute lymphoblastic leukemia.

The Mossé Laboratory studies the role of the anaplastic lymphoma kinase (ALK) oncogene in the initiation and progression of neuroblastoma, with a focus on developing innovative therapeutic strategies for patients with this often lethal disease.

The Mostoufi-Moab Lab investigates the epidemiology and mechanisms of endocrine late effects, aiming to discover and translate new knowledge into novel treatments for endocrine outcomes in survivors of childhood cancer.

The Olson Lab aims to enhance diagnostics and treatment for bone marrow failure (BMF) syndromes and improve outcomes of hematopoietic stem cell transplantation (HSCT).

The Seif Laboratory are focused on patient-centered interventions to improve outcomes, quality of life, and health equity for pediatric patients with leukemia.

The Tan Laboratory studies transcriptional regulation during development and disease, involving transcription factors and epigenetic factors in a 3D chromosomal environment. They use genomics and modeling to study embryonic hematopoiesis, T cell differentiation, and pediatric leukemia.

The Tasian Laboratory focuses on the bench-to-bedside investigation of precision medicine therapies for high-risk childhood leukemias.

The Teachey Lab studies signal transduction disruptions in leukemic cells to identify targeted cancer inhibitors and immunotherapies for treating children with high-risk leukemias and autoimmune lymphoproliferative syndrome.

The Thomas-Tikhonenko Lab focuses on the pathobiology of solid and blood cancers, particularly lymphomas and leukemias driven by MYC overexpression. They mainly study RNA-based regulatory mechanisms like microRNAs and alternative mRNA splicing.

The Tong laboratory studies cytokine receptor and ubiquitin signaling in hematopoietic stem cells, bone marrow failure, and leukemia.

The Weitzman Lab aims to understand host responses to viral infections and the cellular environments viruses encounter and manipulate. They use biochemistry, molecular biology, genetics, and cell biology in their integrated studies.